NCT02502786View on ClinicalTrials.gov

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Recurrent Osteosarcoma
Interventions
BIOLOGICAL

humanized anti-GD2 antibody

DRUG

GM-CSF

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

MD ANDERSON CANCER CENTER (Data Collection Only), Houston

90027

Children's Hospital of Los Angeles (Data Collection Only), Los Angeles

Sponsors

Collaborators (1)

Y-mAbs Therapeutics
All Listed Sponsors
collaborator

Children's Hospital Los Angeles

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Y-mAbs Therapeutics

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER